ranQ
ranQ
ranQ
DirectoryIndustriesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The first Swiss company directory, built to boost AI visibility.

Product
  • Pricing
  • Directory
  • Industries
Company
  • About
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint742,805 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical IndustrySchlierenVirometix AG
Virometix AG Logo
Verified· 3 sources

Virometix AG

Summary

About the company

The core activity of Virometix AG is the development of pharmaceuticals and therapeutics, particularly in the fields of oncology and virology, using live biotherapeutics and other innovative technologies.

AI-generated
Offering

Products & services

Industry:Pharmaceutical Industry
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
✓ Offered
5
Technology platform for synthetic vaccines
Structure-based, fully synthetic nanoparticle vaccines to elicit targeted, robust and long-lasting immune responses; SVLP platform with synthetic peptidomimetics, built-in adjuvants and simplified manufacturing.
Pneumococcal vaccine candidate V-212
Serotype-independent, fully synthetic vaccine candidate against Streptococcus pneumoniae with conserved epitopes on SVLP nanoparticles; studied preclinically for broad immunity against different serotypes.
RSV vaccine candidate
Epitope-specific vaccine candidate against Respiratory Syncytial Virus (RSV) based on the SVLP platform; candidate V-306 was described in a Phase I study as safe, well tolerated and immunogenic.
Co-development partnerships for vaccine development
Co-development partnerships for vaccines against pneumococcus, cervical cancer, respiratory viruses and other selected infectious or chronic diseases.
SVLP technology partnerships and R&D collaborations
Technology partnerships around the SVLP platform as well as R&D collaborations in the areas of monoclonal antibodies, formulation of biologics and peptides, and drug delivery.
Press

Media

November 13, 2025Media
Virometix completes $15 million financing round
startupticker.ch
July 23, 2020Media
Biotech startup Virometix obtains CHF 7.5 M in a series B round
startupticker.ch
March 16, 2020Media
Virometix to kick off in-human studies of its first vaccine candidate
startupticker.ch
February 4, 2019Media
Anna Sumeray takes the lead at Virometix
startupticker.ch

Knowledge

No knowledge articles yet

Once Virometix AG has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Virometix AG in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Virometix AG by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Virometix AG to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Wagistrasse 14
8952 Schlieren

At a glance

Legal form
Corporation
UID
CHE-115.105.074
Founded
2009 · 17 years
Last commercial register change
July 13, 2026
Employees
11 to 20

Similar companies

SA
Stallergenes AG
Dietlikon
TP
Takeda Pharma AG
Glattpark (Opfikon)
AM
A. Menarini GmbH
Zurich
PL
Prometheus Life Technologies AG
Dübendorf